Total Payments
$5,242
2024 Payments
$1,018
Companies
33
Transactions
290
Medicare Patients
2,245
Medicare Billing
$224,848
Payment Breakdown by Category
Food & Beverage$5,242 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,242 | 290 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,179 | 73 | $0 (2024) |
| GlaxoSmithKline, LLC. | $695.02 | 32 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $564.33 | 35 | $0 (2024) |
| PFIZER INC. | $559.55 | 32 | $0 (2024) |
| Lilly USA, LLC | $232.16 | 14 | $0 (2024) |
| Novo Nordisk Inc | $218.62 | 11 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $163.59 | 7 | $0 (2024) |
| Amgen Inc. | $158.52 | 7 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $149.08 | 8 | $0 (2024) |
| Indivior Inc. | $142.70 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,018 | 55 | ABBVIE INC. ($233.57) |
| 2023 | $1,265 | 68 | ABBVIE INC. ($477.41) |
| 2022 | $854.03 | 46 | ABBVIE INC. ($297.73) |
| 2021 | $204.51 | 13 | AbbVie Inc. ($170.50) |
| 2020 | $685.82 | 35 | Novo Nordisk Inc ($131.91) |
| 2019 | $421.24 | 24 | PFIZER INC. ($60.85) |
| 2018 | $349.92 | 22 | Indivior Inc. ($67.92) |
| 2017 | $443.66 | 27 | AstraZeneca Pharmaceuticals LP ($103.40) |
All Payment Transactions
290 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/25/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $10.71 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.82 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $29.37 | General |
| Category: VACCINES | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: Respiratory | ||||||
| 10/04/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: RESPIRATORY | ||||||
| 09/20/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: NEUROSCIENCE | ||||||
| 09/09/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Diabetes | ||||||
| 08/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Respiratory | ||||||
| 08/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Diabetes | ||||||
| 08/05/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: RESPIRATORY | ||||||
| 07/22/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Inflammation | ||||||
| 07/03/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $7.19 | General |
| Category: NEUROSCIENCE | ||||||
| 06/25/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: IMMUNOLOGY | ||||||
| 06/25/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: NEUROSCIENCE | ||||||
| 06/20/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: PAIN | ||||||
| 06/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: RESPIRATORY | ||||||
| 06/03/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $31.31 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 482 | 857 | $104,379 | $56,021 |
| 2022 | 12 | 584 | 1,070 | $117,655 | $60,985 |
| 2021 | 17 | 613 | 885 | $128,376 | $61,808 |
| 2020 | 15 | 566 | 739 | $114,430 | $46,034 |
Total Patients
2,245
Total Services
3,551
Medicare Billing
$224,848
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 45 | 333 | $24,975 | $15,626 | 62.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 79 | 79 | $14,615 | $10,849 | 74.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 105 | 151 | $24,915 | $10,217 | 41.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 69 | 96 | $24,000 | $8,611 | 35.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 16 | 16 | $5,110 | $4,490 | 87.9% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 20 | 21 | $5,775 | $3,406 | 59.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 67 | 67 | $1,675 | $1,333 | 79.6% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 16 | 16 | $1,040 | $520.00 | 50.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 39 | 52 | $1,040 | $436.80 | 42.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 11 | 11 | $484.00 | $357.50 | 73.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 15 | 15 | $750.00 | $173.46 | 23.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 65 | 447 | $33,505 | $20,888 | 62.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 105 | 105 | $19,425 | $14,962 | 77.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 107 | 159 | $26,235 | $9,906 | 37.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 68 | 101 | $25,250 | $8,714 | 34.5% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 12 | 12 | $3,300 | $2,159 | 65.4% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 87 | 87 | $2,175 | $1,770 | 81.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 17 | 20 | $2,400 | $924.50 | 38.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 19 | 19 | $1,235 | $612.61 | 49.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 16 | 16 | $1,600 | $515.78 | 32.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 58 | 74 | $1,480 | $219.30 | 14.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 15 | 15 | $750.00 | $169.95 | 22.7% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 15 | 15 | $300.00 | $144.11 | 48.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 116 | 204 | $33,660 | $13,740 | 40.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 88 | 88 | $16,280 | $12,740 | 78.3% |
About Dr. David Marks, M.D
Dr. David Marks, M.D is a Addiction Medicine healthcare provider based in Ansonia, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1841486149.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Marks, M.D has received a total of $5,242 in payments from pharmaceutical and medical device companies, with $1,018 received in 2024. These payments were reported across 290 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($5,242).
As a Medicare-enrolled provider, Marks has provided services to 2,245 Medicare beneficiaries, totaling 3,551 services with total Medicare billing of $224,848. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Internal Medicine
- Location Ansonia, CT
- Active Since 09/20/2007
- Last Updated 12/07/2020
- Taxonomy Code 2083A0300X
- Entity Type Individual
- NPI Number 1841486149
Products in Payments
- UBRELVY (Drug) $826.99
- TRELEGY ELLIPTA (Drug) $447.29
- ELIQUIS (Drug) $369.05
- BREZTRI (Drug) $251.45
- QULIPTA (Drug) $224.84
- FARXIGA (Drug) $189.79
- VRAYLAR (Drug) $187.88
- XIFAXAN (Drug) $172.58
- NURTEC ODT (Drug) $157.72
- Ozempic (Drug) $157.34
- CHANTIX (Drug) $116.43
- SUBLOCADE (Drug) $109.50
- SYMBICORT (Drug) $107.90
- ANORO ELLIPTA (Drug) $92.27
- Trudhesa (Drug) $91.87
- MIGRANAL (Drug) $90.98
- NUCALA (Biological) $87.44
- TRULICITY (Drug) $86.17
- MYDAYIS (Drug) $76.49
- STIOLTO RESPIMAT (Drug) $74.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.